Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV ...

With Eylea biosimilar competition creeping in and Roche’s Vabsymo jockeying for market share in key indications, Regeneron is ...

Regeneron (NASDAQ:REGN) announced Tuesday that Eylea HD, the high-dose version of its blockbuster eye care medication Eylea ...

The stock's rise snapped a five-day losing streak.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $1086.64, a high ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA ...

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared ...

This was the stock's fifth consecutive day of losses.

Leerink Partners analyst David Risinger maintained a Hold rating on Regeneron (REGN – Research Report) on December 16. The company’s shares ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...